Posts by John

Innate Pharma has finished dose-escalation enrollment for IPH4502, a Nectin-4 targeting ADC. Learn about this milestone in solid tumor clinical research.

Celldex Therapeutics reports that its monoclonal antibody failed to meet primary endpoints in a Phase II trial for prurigo nodularis. Read the latest.

Explore how the UK’s new clinical trial regulations empower pharmacists to enhance patient safety and streamline drug research through improved oversight.

Agios Pharmaceuticals halts clinical development of tebapivat for sickle cell disease. Learn why the Phase 2 ENERGIZE trial results led to this decision.

IMUNON reports positive Phase 2 data for IMNN-001 in ovarian cancer, showing a significant reduction in residual disease post-surgery. Learn the details.

Armata Pharmaceuticals has submitted a Phase 3 trial protocol for AP-SA02, a novel bacteriophage therapy targeting life-threatening S. aureus bacteremia.

Is your clinical site compliant? Discover essential strategies for managing informed consent and avoiding FDA regulatory warnings in medical research.

AI-designed drugs are now entering clinical trials. Learn how these computational breakthroughs are navigating the critical bridge to human medicine.

Healx has begun human dosing for HLX-4310, a novel therapy for metastatic osteosarcoma. Discover how this AI-driven trial aims to transform bone cancer care.

New platforms are allowing bets on clinical trial outcomes, sparking ethical concerns among healthcare leaders about integrity and patient safety.